Liposits G, Lichtman S M
Department of Oncology, Odense University Hospital, J.B. Winsløws Vej 4., 5000 Odense C, Denmark.
Department of Clinical Research, University of Southern Denmark, Odense, J.B. Winsløws Vej 19.3, 5000 Odense C, Denmark.
Gynecol Oncol Rep. 2021 Jan 24;35:100710. doi: 10.1016/j.gore.2021.100710. eCollection 2021 Feb.
•Older patients are still underrepresented in randomized controlled clinical trials.•Older patients receiving PARP-inhibitors tend to achieve shorter PFS, even those considered fit.•Older patients experience more side effects, than their younger counterparts.•Prospective "real-world" data is needed in unselected older women with ovarian cancer receiving PARP-inhibitors.
•老年患者在随机对照临床试验中的代表性仍然不足。
•接受PARP抑制剂的老年患者往往无进展生存期较短，即使是那些被认为健康的患者。
•老年患者比年轻患者经历更多的副作用。
•需要针对未经过挑选、接受PARP抑制剂治疗的老年卵巢癌女性患者的前瞻性“真实世界”数据。
